查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089694

萊姆病市場規模、佔有率和趨勢分析報告：按類型、地區和細分市場預測（2026-2033 年）

Lyme Disease Market Size, Share & Trends Analysis Report By Type (By Therapeutics, By Diagnostic ), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

萊姆病市場概況

2025年全球萊姆病市場價值為29億美元，預計將從2026年的31億美元成長到2033年的58億美元，2026年至2033年的複合年成長率為9.4%。

到2025年，北美萊姆病市場將佔據全球市場最大佔有率，達到43.5%。由於北美和歐洲蜱感染疾病的發生率不斷上升，該市場正經歷顯著成長。

氣候變遷、蜱蟲棲息地擴張以及戶外休閒活動的增加，是導致全球萊姆病發病率上升的重要因素。此外，大眾對蜱蟲叮咬相關健康風險的認知不斷提高，促進了早期診斷和及時治療。各國政府和公共衛生機構也積極推動監測計畫和宣傳宣傳活動，以減輕疾病負擔。萊姆病報告病例的增加，使得對有效診斷和治療方法的需求強勁，從而推動了市場擴張。此外，已開發國家醫療保健支出的增加以及感染疾病防治措施的改善，進一步提升了全球萊姆病診斷和治療市場的商業性潛力。

萊姆病市場規模及成長預測（2023-2033）

診斷技術的進步是萊姆病市場成長的另一個大驅動力。除了傳統的血清學檢測外，分子診斷和快速即時檢測解決方案也日益普及，提高了檢測準確性並縮短了診斷時間。醫療機構正在採用先進的診斷平台來早期識別萊姆病，從而減少長期併發症和治療成本。此外，生技公司和診斷設備製造商加大研發投入，加速了市場創新。自動化檢測系統、多重檢測和基於生物標記的診斷方法的出現，進一步增強了市場競爭力。研究機構、公共衛生實驗室和私人公司之間日益密切的合作也促進了技術進步，最終推動了高效萊姆病檢測解決方案在全球醫院和實驗室中的廣泛應用。

在對有效治療方案和輔助護理解決方案的需求不斷成長的推動下，萊姆病治療市場也在穩步擴張。四環黴素、青黴素類和頭孢菌素類等抗生素仍是主要的治療標準，口服藥物在處方藥中佔很大比例。然而，隨著人們對「治療後萊姆病綜合症（PTLDS）」的認知不斷提高，對輔助護理和症狀管理療法的興趣也日益濃厚，這為市場創造了新的商機。製藥公司正積極探索聯合治療、新型抗感染藥物和候選藥物，以滿足疾病後期持續症狀和併發症方面併發症的需求。此外，對感染疾病研發投入的增加，以及政府對蜱傳疾病控制計畫的積極支持，正在加速治療方法的發展。這些因素共同作用，持續增強了全球萊姆病市場的長期成長前景。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：萊姆病市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：萊姆病市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 治療方法
  • 診斷

第5章：萊姆病市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第6章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Pfizer Inc.
    • GSK plc
    • Sanofi SA
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • DiaSorin SpA
Product Code: GVR-4-68040-935-5

Lyme Disease Market Summary

The global lyme disease market size was valued at USD 2.9 billion in 2025 and is projected to grow from USD 3.1 billion in 2026 to USD 5.8 billion by 2033, growing at a CAGR of 9.4% from 2026 to 2033. North America Lyme Disease market held the largest share of 43.5% of the global market in 2025. The market is experiencing substantial growth due to the increasing prevalence of tick-borne infections across North America and Europe.

Climate change, expanding tick habitats, and rising outdoor recreational activities have significantly contributed to the growing incidence of Lyme disease globally. In addition, greater public awareness regarding the health risks associated with tick exposure has encouraged early diagnosis and timely treatment adoption. Governments and public health organizations are also actively promoting surveillance programs and awareness campaigns to reduce disease burden. The rising number of reported Lyme disease cases has created strong demand for effective diagnostics and therapeutics, supporting market expansion. Furthermore, increasing healthcare expenditure and improved access to infectious disease management in developed countries continue to strengthen the commercial potential of the lyme disease market across both diagnostic and therapeutic segments globally.

Lyme disease market size and growth forecast (2023-2033)

Advancements in diagnostic technologies are another major factor driving the growth of the lyme disease market. Traditional serological testing methods are increasingly being complemented by molecular diagnostics and rapid point-of-care testing solutions that improve detection accuracy and reduce diagnosis time. Healthcare providers are adopting advanced diagnostic platforms to identify Lyme disease during its early stages, helping reduce long-term complications and treatment costs. In addition, growing investments by biotechnology and diagnostic companies in research and development activities are accelerating innovation within the market. The emergence of automated laboratory systems, multiplex assays, and biomarker-based diagnostic approaches is further enhancing market competitiveness. Increasing collaborations between research institutes, public health laboratories, and private companies are also contributing to technological advancements, ultimately supporting broader adoption of efficient Lyme disease testing solutions in both hospital and laboratory settings worldwide.

The therapeutics segment of the Lyme Disease market is also expanding steadily due to increasing demand for effective treatment options and supportive care solutions. Antibiotics such as tetracyclines, penicillins, and cephalosporins remain the primary standard of care, with oral therapies accounting for a significant share of prescriptions. However, growing recognition of Post-Treatment Lyme Disease Syndrome (PTLDS) has increased interest in supportive and symptom management therapies, creating new commercial opportunities within the market. Pharmaceutical companies are actively exploring combination therapies, novel anti-infective agents, and pipeline candidates to address unmet clinical needs associated with persistent symptoms and late-stage disease complications. Additionally, rising investments in infectious disease research and favorable government support for tick-borne disease management programs are accelerating therapeutic development activities. These factors collectively continue to strengthen long-term growth prospects for the global Lyme Disease market.

Global Lyme Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Lyme disease market report based on type, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Therapeutic
    • Drug Class
    • Tetracyclines
    • Penicillins
    • Cephalosporins
    • Macrolides
    • Other Anti-infective Therapies
    • Treatment Modality
    • Antibiotic Therapy
    • Supportive & Symptom Management
    • Route of Administration
    • Oral
    • Injectable / Intravenous
    • Disease Stage
    • Early-Stage Lyme Disease
    • Late-Stage Lyme Disease
    • Post-Treatment Lyme Disease Syndrome (PTLDS)
  • Diagnostic
    • Test Type
    • Serological Testing
    • Molecular Diagnostics
    • Culture-based Diagnostics
    • Rapid & Point-of-Care Diagnostics
    • Sample Type
    • Blood & Serum Samples
    • Cerebrospinal Fluid (CSF)
    • Synovial Fluid
    • Tissue Biopsy Samples
    • End User
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Public Health Laboratories
    • Research Institutes
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lyme Disease Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lyme Disease Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Therapeutic
    • 4.4.1. Therapeutic Market, 2021 - 2033 (USD Million)
    • 4.4.2. Drug Class
      • 4.4.2.1. Drug Class Market, 2021 - 2033 (USD Million)
      • 4.4.2.2. Tetracyclines
        • 4.4.2.2.1. Tetracyclines Market, 2021 - 2033 (USD Million)
      • 4.4.2.3. Penicillins
        • 4.4.2.3.1. Penicillins Market, 2021 - 2033 (USD Million)
      • 4.4.2.4. Cephalosporins
        • 4.4.2.4.1. Cephalosporins Market, 2021 - 2033 (USD Million)
      • 4.4.2.5. Macrolides
        • 4.4.2.5.1. Macrolides Market, 2021 - 2033 (USD Million)
      • 4.4.2.6. Other Anti-infective Therapies
        • 4.4.2.6.1. Other Anti-infective Therapies Market, 2021 - 2033 (USD Million)
    • 4.4.3. Treatment Modality
      • 4.4.3.1. Treatment Modality Market, 2021 - 2033 (USD Million)
      • 4.4.3.2. Antibiotic Therapy
        • 4.4.3.2.1. Antibiotic Therapy Market, 2021 - 2033 (USD Million)
      • 4.4.3.3. Supportive & Symptom Management
        • 4.4.3.3.1. Supportive & Symptom Management Market, 2021 - 2033 (USD Million)
    • 4.4.4. Route of Administration
      • 4.4.4.1. Route of Administration Market, 2021 - 2033 (USD Million)
      • 4.4.4.2. Oral
        • 4.4.4.2.1. Oral Market, 2021 - 2033 (USD Million)
      • 4.4.4.3. Injectable / Intravenous
        • 4.4.4.3.1. Injectable / Intravenous Market, 2021 - 2033 (USD Million)
    • 4.4.5. Disease Stage
      • 4.4.5.1. Disease Stage Market, 2021 - 2033 (USD Million)
      • 4.4.5.2. Early-Stage Lyme Disease
        • 4.4.5.2.1. Early-Stage Lyme Disease Market, 2021 - 2033 (USD Million)
      • 4.4.5.3. Late-Stage Lyme Disease
        • 4.4.5.3.1. Late-Stage Lyme Disease Market, 2021 - 2033 (USD Million)
      • 4.4.5.4. Post-Treatment Lyme Disease Syndrome (PTLDS)
        • 4.4.5.4.1. Post-Treatment Lyme Disease Syndrome (PTLDS) Market, 2021 - 2033 (USD Million)
  • 4.5. Diagnostic
    • 4.5.1. Diagnostic Market, 2021 - 2033 (USD Million)
    • 4.5.2. Test Type
      • 4.5.2.1. Test Type Market, 2021 - 2033 (USD Million)
      • 4.5.2.2. Serological Testing
        • 4.5.2.2.1. Serological Testing Market, 2021 - 2033 (USD Million)
      • 4.5.2.3. Molecular Diagnostics
        • 4.5.2.3.1. Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 4.5.2.4. Culture-based Diagnostics
        • 4.5.2.4.1. Culture-based Diagnostics Market, 2021 - 2033 (USD Million)
      • 4.5.2.5. Rapid & Point-of-Care Diagnostics
        • 4.5.2.5.1. Rapid & Point-of-Care Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.5.3. Sample Type
      • 4.5.3.1. Sample Type Market, 2021 - 2033 (USD Million)
      • 4.5.3.2. Blood & Serum Samples
        • 4.5.3.2.1. Blood & Serum Samples Market, 2021 - 2033 (USD Million)
      • 4.5.3.3. Cerebrospinal Fluid (CSF)
        • 4.5.3.3.1. Cerebrospinal Fluid (CSF) Market, 2021 - 2033 (USD Million)
      • 4.5.3.4. Synovial Fluid
        • 4.5.3.4.1. Synovial Fluid Market, 2021 - 2033 (USD Million)
      • 4.5.3.5. Tissue Biopsy Samples
        • 4.5.3.5.1. Tissue Biopsy Samples Market, 2021 - 2033 (USD Million)
    • 4.5.4. End User
      • 4.5.4.1. End User Market, 2021 - 2033 (USD Million)
      • 4.5.4.2. Hospitals & Clinics
        • 4.5.4.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
      • 4.5.4.3. Diagnostic Laboratories
        • 4.5.4.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
      • 4.5.4.4. Public Health Laboratories
        • 4.5.4.4.1. Public Health Laboratories Market, 2021 - 2033 (USD Million)
      • 4.5.4.5. Research Institutes
        • 4.5.4.5.1. Research Institutes Market, 2021 - 2033 (USD Million)

Chapter 5. Lyme Disease Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2025 & 2033
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 5.4. North America
    • 5.4.1. North America Lyme Disease Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Target Disease Prevalence
      • 5.4.2.3. Regulatory Framework
      • 5.4.2.4. Reimbursement Framework
      • 5.4.2.5. U.S. Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Regulatory Framework
      • 5.4.3.4. Reimbursement Framework
      • 5.4.3.5. Canada Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Target Disease Prevalence
      • 5.4.4.3. Regulatory Framework
      • 5.4.4.4. Reimbursement Framework
      • 5.4.4.5. Mexico Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Europe
    • 5.5.1. Europe Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Target Disease Prevalence
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Reimbursement Framework
      • 5.5.2.5. Uk Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Target Disease Prevalence
      • 5.5.3.3. Regulatory Framework
      • 5.5.3.4. Reimbursement Framework
      • 5.5.3.5. Germany Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Target Disease Prevalence
      • 5.5.4.3. Regulatory Framework
      • 5.5.4.4. Reimbursement Framework
      • 5.5.4.5. France Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Target Disease Prevalence
      • 5.5.5.3. Regulatory Framework
      • 5.5.5.4. Reimbursement Framework
      • 5.5.5.5. Italy Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Target Disease Prevalence
      • 5.5.6.3. Regulatory Framework
      • 5.5.6.4. Reimbursement Framework
      • 5.5.6.5. Spain Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.7. Denmark
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Target Disease Prevalence
      • 5.5.7.3. Regulatory Framework
      • 5.5.7.4. Reimbursement Framework
      • 5.5.7.5. Denmark Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.8. Sweden
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Target Disease Prevalence
      • 5.5.8.3. Regulatory Framework
      • 5.5.8.4. Reimbursement Framework
      • 5.5.8.5. Sweden Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.9. Norway
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Target Disease Prevalence
      • 5.5.9.3. Regulatory Framework
      • 5.5.9.4. Reimbursement Framework
      • 5.5.9.5. Norway Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Target Disease Prevalence
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. Reimbursement Framework
      • 5.6.2.5. Japan Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Target Disease Prevalence
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. Reimbursement Framework
      • 5.6.3.5. China Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Target Disease Prevalence
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. Reimbursement Framework
      • 5.6.4.5. India Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Target Disease Prevalence
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Reimbursement Framework
      • 5.6.5.5. Australia Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.6. South Korea
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Target Disease Prevalence
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Reimbursement Framework
      • 5.6.6.5. South Korea Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Target Disease Prevalence
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Reimbursement Framework
      • 5.6.7.5. Thailand Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Latin America Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Target Disease Prevalence
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. Reimbursement Framework
      • 5.7.2.5. Brazil Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Target Disease Prevalence
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. Reimbursement Framework
      • 5.7.3.5. Argentina Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Middle East and Africa
    • 5.8.1. Middle East and Africa Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Target Disease Prevalence
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Reimbursement Framework
      • 5.8.2.5. South Africa Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Target Disease Prevalence
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. Reimbursement Framework
      • 5.8.3.5. Saudi Arabia Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Target Disease Prevalence
      • 5.8.4.3. Regulatory Framework
      • 5.8.4.4. Reimbursement Framework
      • 5.8.4.5. UAE Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Target Disease Prevalence
      • 5.8.5.3. Regulatory Framework
      • 5.8.5.4. Reimbursement Framework
      • 5.8.5.5. Kuwait Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Pfizer Inc.
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. GSK plc
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Sanofi S.A.
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Merck & Co., Inc.
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. F. Hoffmann-La Roche Ltd.
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. Abbott Laboratories
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Product Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. Thermo Fisher Scientific Inc.
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Product Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. bioMerieux SA
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Product Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Bio-Rad Laboratories, Inc.
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Product Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. DiaSorin S.p.A.
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Product Benchmarking
      • 6.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Lyme disease market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America Lyme disease market, by country, 2021 - 2033 (USD Million)
  • Table 6 North America Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 7 U.S Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 8 Canada Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 9 Mexico Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 10 Europe Lyme disease market, by country, 2021 - 2033 (USD Million)
  • Table 11 Europe Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 12 UK Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 13 Germany Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 14 France Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 15 Italy Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 16 Spain Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 17 Denmark Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 18 Sweden Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 19 Norway Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 20 Asia Pacific Lyme disease market, by country, 2021 - 2033 (USD Million)
  • Table 21 Asia Pacific Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 22 Japan Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 23 China Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 24 India Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 25 Australia Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 26 South Korea Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 27 Thailand Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 28 Latin America Lyme disease market, by country, 2021 - 2033 (USD Million)
  • Table 29 Latin America Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 30 Brazil Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 31 Argentina Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 32 Middle East & Africa Lyme disease market, by country, 2021 - 2033 (USD Million)
  • Table 33 Middle East & Africa Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 34 South Africa Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 35 Saudi Arabia Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 36 UAE Lyme disease market, by type, 2021 - 2033 (USD Million)
  • Table 37 Kuwait Lyme disease market, by type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Lyme Disease market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Lyme Disease market dynamics
  • Fig. 11 Lyme Disease market: Porter's five forces analysis
  • Fig. 12 Lyme Disease market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Therapeutic market, 2021 - 2033 (USD Million)
  • Fig. 15 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 16 Tetracyclines market, 2021 - 2033 (USD Million)
  • Fig. 17 Penicillins market, 2021 - 2033 (USD Million)
  • Fig. 18 Cephalosporins market, 2021 - 2033 (USD Million)
  • Fig. 19 Macrolides market, 2021 - 2033 (USD Million)
  • Fig. 20 Other Anti-infective Therapies market, 2021 - 2033 (USD Million)
  • Fig. 21 Treatment Modality market, 2021 - 2033 (USD Million)
  • Fig. 22 Antibiotic Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 Supportive & Symptom Management market, 2021 - 2033 (USD Million)
  • Fig. 24 Route of Administration market, 2021 - 2033 (USD Million)
  • Fig. 25 Oral market, 2021 - 2033 (USD Million)
  • Fig. 26 Injectable / Intravenous market, 2021 - 2033 (USD Million)
  • Fig. 27 Disease Stage market, 2021 - 2033 (USD Million)
  • Fig. 28 Early-Stage Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 29 Late-Stage Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 30 Post-Treatment Lyme Disease Syndrome (PTLDS) market, 2021 - 2033 (USD Million)
  • Fig. 31 Diagnostic market, 2021 - 2033 (USD Million)
  • Fig. 32 Test Type market, 2021 - 2033 (USD Million)
  • Fig. 33 Serological Testing market, 2021 - 2033 (USD Million)
  • Fig. 34 Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 35 Culture-based Diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 36 Rapid & Point-of-Care Diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 37 Sample Type market, 2021 - 2033 (USD Million)
  • Fig. 38 Blood & Serum Samples market, 2021 - 2033 (USD Million)
  • Fig. 39 Cerebrospinal Fluid (CSF) market, 2021 - 2033 (USD Million)
  • Fig. 40 Synovial Fluid market, 2021 - 2033 (USD Million)
  • Fig. 41 Tissue Biopsy Samples market, 2021 - 2033 (USD Million)
  • Fig. 42 End User market, 2021 - 2033 (USD Million)
  • Fig. 43 Hospitals & Clinics market, 2021 - 2033 (USD Million)
  • Fig. 44 Diagnostic Laboratories market, 2021 - 2033 (USD Million)
  • Fig. 45 Public Health Laboratories market, 2021 - 2033 (USD Million)
  • Fig. 46 Research Institutes market, 2021 - 2033 (USD Million)
  • Fig. 47 Lyme Disease market revenue, by region
  • Fig. 48 Regional marketplace: Key takeaways
  • Fig. 49 North America Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 50 U.S. country dynamics
  • Fig. 51 U.S. Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 52 Canada country dynamics
  • Fig. 53 Canada Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 54 Mexico country dynamics
  • Fig. 55 Mexico Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 56 Europe Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 57 UK country dynamics
  • Fig. 58 UK Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 59 Germany country dynamics
  • Fig. 60 Germany Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 61 France country dynamics
  • Fig. 62 France Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 63 Italy country dynamics
  • Fig. 64 Italy Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 65 Spain country dynamics
  • Fig. 66 Spain Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 67 Denmark country dynamics
  • Fig. 68 Denmark Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 69 Sweden country dynamics
  • Fig. 70 Sweden Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 71 Norway country dynamics
  • Fig. 72 Norway Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 73 Asia Pacific Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 74 Japan country dynamics
  • Fig. 75 Japan Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 76 China country dynamics
  • Fig. 77 China Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 78 India country dynamics
  • Fig. 79 India Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 80 Australia country dynamics
  • Fig. 81 Australia Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 82 South Korea country dynamics
  • Fig. 83 South Korea Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 84 Thailand country dynamics
  • Fig. 85 Thailand Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 86 Latin America Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 87 Brazil country dynamics
  • Fig. 88 Brazil Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 89 Argentina country dynamics
  • Fig. 90 Argentina Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 91 MEA Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 92 South Africa country dynamics
  • Fig. 93 South Africa Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 94 Saudi Arabia country dynamics
  • Fig. 95 Saudi Arabia Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 96 UAE country dynamics
  • Fig. 97 UAE Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 98 Kuwait country dynamics
  • Fig. 99 Kuwait Lyme Disease market, 2021 - 2033 (USD Million)
  • Fig. 100 Company categorization
  • Fig. 101 Company market position analysis
  • Fig. 102 Strategic framework